Ciprofibrate

When ATH:
C10AB08

Pharmacological action.
Hypolipidemic.

Application.

Endogenous hypercholesterolemia (Isolation, associate) and hypertriglyceridemia, not correctable diet and physical activity; risk factors hypercholesterolemia.

Contraindications.

Hypersensitivity, renal, hepatic failure, pregnancy, lactation, childhood.

Side effects.

Headache, nausea, weakness, fatigue, myositis, mialgii, exacerbation of cholelithiasis, increase in serum transaminases, creatinine, allergic skin reactions.

Cooperation.

Incompatible with hepatotoxic agents (maleate pereksillita, MAO inhibitors), It increases the effect of indirect anticoagulants (antivitamin K). Nicotinic acid derivatives, etc.. cholesterol-lowering drugs increase the effectiveness of the application.

Dosing and Administration.

Inside, by 100 - 200 mg per day.

Precautions.

With the ineffectiveness of 3-6 months of receiving the needed combination therapy. At the time of treatment is required careful monitoring of the level and activity of hepatic transaminases: if the activity of serum ALT exceeds 100 u, ciprofibrate cancel. When concomitant administration with indirect anticoagulants (under the control of prothrombin) it is recommended to reduce the dose of the latter on 30%.

Hypoalbuminemia necessitates dose reduction (selected individually).